Dragonfly Therapeutics, Inc. logo

Dragonfly Therapeutics, Inc.

We are a discovery-stage company developing drugs targeted at natural killer cells and other cells of the body's innate immune system, to eliminate cancer. Dragonfly Therapeutics (formerly Equipoise Therapeutics) is a discovery-stage company developing novel first-in-class therapeutics targeted at natural killer cells as well as other cells of the innate immune system. The company is located at LabCentral.

Dragonfly Therapeutics was founded by Dr. Tyler Jacks, head of the Koch Institute at MIT; Bill Haney, a longtime tech entrepreneur and investor, and Dr. David Raulet, one of the worlds leading experts in Natural Killer (NK) cell biology.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.dragonflytx.com
Founded2015
Disease Focus
Development Stage
STOCK CODENon Listed
Address
35 Gatehouse Drive,MA 02451
Waltham
United States
Email
Contact Number
+1 617-588-0086

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/dragonfly-therapeutics-inc.” connections=”true” suffix=””]

Dragonflys TriNKET_ platform generates bridges designed to bind to proteins found on the surface of tumor cells and NK cells, to stimulate NK cells. Once activated and aware of the presence of the cancer cells, NK cells attack tumors directly while also enlisting the support of T and B cells.

In Jun 2017, Celgene acquires an exclusive option to in-license worldwide rights for up to four therapeutic candidates from Dragonfly, with potential utility in the treatment of acute myeloid leukemia, multiple myeloma, and additional hematological malignancies. The collaboration includes a $33 Mn upfront payment, and potential future milestone and royalty payments.